The US Food and Drug Administration has recommended that the breast cancer indication be removed from Avastin (bevacizumab), which is used in combination with paclitaxel, because the treatment does not prolong overall survival. However, the European Medicines Agency said it will allow the indication to remain because there is still clinical benefit based on progression free survival.
